Laudexium metilsulfate

From Wikipedia, the free encyclopedia
Laudexium metilsulfate
Laudexium metilsulfate.svg
Clinical data
Other namesLaudolissin
Routes of
administration		IV
Legal status
Legal status
  • discontinued from clinical use
Pharmacokinetic data
Bioavailability100% (IV)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC54H80N2O16S2
Molar mass1077.35 g·mol−1
3D model (JSmol)
 ☒NcheckY (what is this?)  

Laudexium metilsulfate is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in surgical anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Laudexium[1] is no longer used in clinical practice, though it was introduced clinically in the early 1950s.[citation needed] It has about half the potency, a slower onset of action and a duration of action much longer than that of d-tubocurarine.[2] As with all clinically established (as well as experimental agents) with a non-depolarizing mechanism of action, its pharmacological action can be antagonized by anticholinesterases.

The displacement of laudexium from clinical use was assured owing to recurrent reports of significant post-operative re-curarization.[3]

References[]

  1. ^ Taylor EP (1952). "Synthetic neuromuscular blocking agents. Part II. Bis(quaternary ammonium salts) derived from laudanosine". J Chem Soc: 142–145. doi:10.1039/JR9520000142.
  2. ^ Hunter AR (February 1955). "The action of laudexium in man and experimental animals". British Journal of Anaesthesia. 27 (2): 73–9. doi:10.1093/bja/27.2.73. PMID 13230365.
  3. ^ Collier HO, Macauley B (September 1952). "The pharmacological properties of "laudolissin" a long-acting curarizing agent". British Journal of Pharmacology and Chemotherapy. 7 (3): 398–408. doi:10.1111/j.1476-5381.1952.tb00707.x. PMC 1509112. PMID 12978243.

External links[]

Retrieved from ""